This review examines the cardiovascular health implications of breast cancer therapies across the life course, with a focus on treatments associated with cardiovascular adverse effects, exacerbation of cardiovascular risk factors, and increased cardiovascular disease risk — including in younger, premenopausal women.
For long-term breast cancer survivors, cardiovascular adverse effects of treatment may pose a greater threat to overall health than the cancer itself; the rising incidence of breast cancer in younger, premenopausal women creates a distinct population with unique cardio-oncology needs.
The abstract does not report primary data, specific patient populations, or quantitative outcomes — limiting assessment of effect sizes or direct clinical comparisons.
Cardiology practitioners should stay current on evolving breast cancer therapies and their cardiovascular risks, particularly for younger and long-term survivors. Integration of cardio-oncology care is increasingly important for this growing patient population.
Explore related topics
